Rapid Urine Test Evaluated for Helicobacter Pylori Infection
|
By LabMedica International staff writers Posted on 26 Jun 2014 |

Image: Rapirun Helicobacter pylori Antibody Stick. The urine sample is considered positive when two red bands at the test line and control line (arrows) are observed after 15 minutes and is considered negative when only the control line is observed. The absence of a control line indicates an invalid result (Photo courtesy of Duc T Quach).

Image: The PyloriTek rapid urease test to detect Helicobacter pylori (Photo courtesy of Serim Research Co.).
A rapid urine test based on enzyme-linked immunosorbent assay (ELISA) has been developed for the detection of anti-Helicobacter Pylori antibodies in urine.
Several methods to diagnose H. pylori infection have been developed, among which the urea breath test (UBT) is currently regarded as the most accurate assay, but the UBT is still expensive and not widely available in many countries.
Scientists at the Ho Chi Minh City Medicine and Pharmacy University (Vietnam) working with Japanese colleagues, enrolled 200 patients undergoing upper gastrointestinal endoscopy from October 2012 to December 2012. Three biopsies were taken from each patient: two for histologic examination and one for the rapid urease test (RUT).
The biopsy for RUT was taken from the greater curvature of the corpus, about 2 cm above the atrophic border. This biopsy location has been reported to optimize the sensitivity of the PyloriTek RUT to detect H. pylori (Serim Research Co.; Elkhart, IN, USA). Urine samples were collected and were processed within one hour of collection for the detection of antibodies against H. pylori using the Rapirun Helicobacter pylori Antibody Stick (Otsuka Pharmaceutical Co., Ltd.; Tokyo, Japan). The test measures human immunoglobulin G (IgG) antibodies against H. pylori in urine using the principle of immunochromatography.
Of the 200 patients, 111 (55.5%) were diagnosed as being H. pylori positive. The sensitivity, specificity, and accuracy of the Rapirun Stick test were 84.7%, 89.9%, and 87.0%, respectively. There were 17 (8.5%) false-negative patients and 9 (4.5%) false-positive patients. Of the 24 patients with gastro-duodenal ulcer, 22 (91.7%) had H. pylori infection. However, 7 of 22 (31.8%) patients with reflux esophagitis also had the infection.
The authors demonstrated the usefulness of the Rapirun Stick test for the diagnosis of H. pylori infection in a Vietnamese population and the sensitivity, specificity, and accuracy of the Rapirun Stick test were high. In several patients, RUT and histologic examination produced false-negative or false-positive results, leading to the possible misdiagnosis of H. pylori infection. The study was published on May 7, 2014, in the World Journal of Gastroenterology.
Related Links:
Ho Chi Minh University of Medicine
Serim Research Co.
Otsuka Pharmaceutical Co.
Several methods to diagnose H. pylori infection have been developed, among which the urea breath test (UBT) is currently regarded as the most accurate assay, but the UBT is still expensive and not widely available in many countries.
Scientists at the Ho Chi Minh City Medicine and Pharmacy University (Vietnam) working with Japanese colleagues, enrolled 200 patients undergoing upper gastrointestinal endoscopy from October 2012 to December 2012. Three biopsies were taken from each patient: two for histologic examination and one for the rapid urease test (RUT).
The biopsy for RUT was taken from the greater curvature of the corpus, about 2 cm above the atrophic border. This biopsy location has been reported to optimize the sensitivity of the PyloriTek RUT to detect H. pylori (Serim Research Co.; Elkhart, IN, USA). Urine samples were collected and were processed within one hour of collection for the detection of antibodies against H. pylori using the Rapirun Helicobacter pylori Antibody Stick (Otsuka Pharmaceutical Co., Ltd.; Tokyo, Japan). The test measures human immunoglobulin G (IgG) antibodies against H. pylori in urine using the principle of immunochromatography.
Of the 200 patients, 111 (55.5%) were diagnosed as being H. pylori positive. The sensitivity, specificity, and accuracy of the Rapirun Stick test were 84.7%, 89.9%, and 87.0%, respectively. There were 17 (8.5%) false-negative patients and 9 (4.5%) false-positive patients. Of the 24 patients with gastro-duodenal ulcer, 22 (91.7%) had H. pylori infection. However, 7 of 22 (31.8%) patients with reflux esophagitis also had the infection.
The authors demonstrated the usefulness of the Rapirun Stick test for the diagnosis of H. pylori infection in a Vietnamese population and the sensitivity, specificity, and accuracy of the Rapirun Stick test were high. In several patients, RUT and histologic examination produced false-negative or false-positive results, leading to the possible misdiagnosis of H. pylori infection. The study was published on May 7, 2014, in the World Journal of Gastroenterology.
Related Links:
Ho Chi Minh University of Medicine
Serim Research Co.
Otsuka Pharmaceutical Co.
Latest Immunology News
- Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
- Study Finds Influenza Often Undiagnosed in Winter Deaths
- Combined Screening Approach Identifies Early Leprosy Cases
- Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
- FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
- Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
- Microfluidic Chip Detects Cancer Recurrence from Immune Response Signals
- Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response
- Immune Signature Identified in Treatment-Resistant Myasthenia Gravis
- New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer
- Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
- Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
- Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
- Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
- Blood Test Could Detect Adverse Immunotherapy Effects
- Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy
Channels
Clinical Chemistry
view channel
Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read moreMolecular Diagnostics
view channel
Cancer-Related Mutations in Immune Cells Linked to Alzheimer’s
Alzheimer’s disease is marked by protein aggregation and inflammatory changes in the brain’s immune system, yet its molecular drivers remain incompletely understood. With aging, human cells accumulate... Read more
Composite Blood Biomarkers Enable Early Detection of Common Cancers
Early diagnosis of colorectal, lung, and ovarian cancers remains challenging, with many patients identified only after tumors have begun to spread. A scalable blood test could expand access to screening,... Read more
Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary
Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read moreHematology
view channel
Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
CareDx (Brisbane, CA, USA) has introduced AlloSeq Nano, a nanopore‑based HLA (human leukocyte antigen) and ABO genotyping solution unveiled at the European Federation for Immunogenetics (EFI) Conference 2026.... Read more
Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
Diffuse large B-cell lymphoma (DLBCL) is the most common form of non-Hodgkin lymphoma and often presents with aggressive clinical behavior. Although many patients respond to standard chemotherapy with... Read moreImmunology
view channel
Immune Aging Clock Quantifies Immunosenescence and Identifies Therapeutic Target
Immune aging undermines host defense and contributes to multiple age-related diseases, yet its heterogeneity complicates measurement and intervention. Clinical laboratories increasingly seek objective... Read more
Study Finds Influenza Often Undiagnosed in Winter Deaths
Seasonal influenza drives substantial excess mortality, yet its contribution is often obscured when infections go undiagnosed near the time of death. Many deaths occur outside hospitals or in older adults... Read morePathology
view channel
Plug-and-Play AI Pathology System Classifies Multiple Cancers from Few Slides
Pathologists are essential for cancer diagnosis and treatment planning, yet a global workforce shortage is straining services. Nearly 20 million new cases are diagnosed each year, and traditional artificial... Read more
AI-Based Assays Support Risk Stratification in Prostate and Breast Cancer
Prostate and breast cancers are among the most commonly diagnosed malignancies worldwide, and heterogeneous disease biology complicates risk stratification and treatment selection. Clinicians increasingly... Read moreTechnology
view channel
AI Tool Predicts Non-Response to Targeted Therapy in Colorectal Cancer
Advanced bowel cancer remains difficult to treat, and many patients receive targeted therapies that do not help them but still cause harm. Clinicians need reliable ways to identify likely responders before... Read more
Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic... Read moreIndustry
view channel
QuidelOrtho Adds Ultra-Fast PCR Platform with LEX Acquisition
QuidelOrtho Corporation has completed the acquisition of LEX Diagnostics for approximately USD 100 million in cash. The transaction adds the LEX VELO System to QuidelOrtho’s portfolio. The platform received U.... Read more
Seegene Showcases Real-Time PCR Data Analytics Platform at ESCMID
Seegene introduced STAgora, a real-time data analytics platform built on aggregated statistical testing data, at ESCMID Global 2026 in Munich, where it also presented an enhanced model of its automated... Read more
Roche Affiliate Expands MRD Portfolio with SAGA Acquisition
Foundation Medicine, Inc., an independent affiliate of Roche, announced plans to expand its monitoring portfolio with SAGA Diagnostics’ Pathlight, a personalized, tumor-informed molecular residual disease... Read more







